⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RIGL News
Rigel Pharmaceuticals Inc. (New)
Form 8-K
sec.gov
RIGL
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
prnewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Form 8-K
sec.gov
ARVN
RIGL
PFE
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
RIGL
PFE
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
prnewswire.com
RIGL
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
globenewswire.com
ARVN
PFE
RIGL
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
globenewswire.com
RIGL
Form 8-K
sec.gov
RIGL
Rigel Reports First Quarter 2026 Financial Results
prnewswire.com
RIGL